- Home
- LIDR vs MYNZ Comparison
LIDR vs MYNZ Comparison
Compare LIDR & MYNZ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LIDR
- MYNZ
- Stock Information
- Founded
- LIDR 2013
- MYNZ 2021
- Country
- LIDR United States
- MYNZ Germany
- Employees
- LIDR N/A
- MYNZ N/A
- Industry
- LIDR Auto Parts:O.E.M.
- MYNZ Biotechnology: Pharmaceutical Preparations
- Sector
- LIDR Consumer Discretionary
- MYNZ Health Care
- Exchange
- LIDR Nasdaq
- MYNZ Nasdaq
- Market Cap
- LIDR 9.8M
- MYNZ 10.5M
- IPO Year
- LIDR N/A
- MYNZ 2021
- Fundamental
- Price
- LIDR $0.59
- MYNZ $3.44
- Analyst Decision
- LIDR Hold
- MYNZ Buy
- Analyst Count
- LIDR 1
- MYNZ 3
- Target Price
- LIDR N/A
- MYNZ $14.00
- AVG Volume (30 Days)
- LIDR 307.0K
- MYNZ 177.3K
- Earning Date
- LIDR 05-13-2025
- MYNZ 04-15-2025
- Dividend Yield
- LIDR N/A
- MYNZ N/A
- EPS Growth
- LIDR N/A
- MYNZ N/A
- EPS
- LIDR N/A
- MYNZ N/A
- Revenue
- LIDR $202,000.00
- MYNZ $893,991.00
- Revenue This Year
- LIDR $2,677.23
- MYNZ $20.94
- Revenue Next Year
- LIDR $409.09
- MYNZ $18.01
- P/E Ratio
- LIDR N/A
- MYNZ N/A
- Revenue Growth
- LIDR N/A
- MYNZ N/A
- 52 Week Low
- LIDR $0.51
- MYNZ $0.18
- 52 Week High
- LIDR $5.15
- MYNZ $8.20
- Technical
- Relative Strength Index (RSI)
- LIDR 41.30
- MYNZ 37.70
- Support Level
- LIDR $0.55
- MYNZ $2.72
- Resistance Level
- LIDR $0.68
- MYNZ $5.34
- Average True Range (ATR)
- LIDR 0.06
- MYNZ 0.55
- MACD
- LIDR 0.01
- MYNZ -0.12
- Stochastic Oscillator
- LIDR 28.83
- MYNZ 27.48
About LIDR AEye Inc.
AEye Inc is a provider of high-performance, active lidar systems for vehicle autonomy, driver-assistance systems (ADAS), and robotic vision applications. The company's software-definable 4Sight Intelligent Sensing Platform combines solid-state active lidar, an optionally fused low-light HD camera, and integrated deterministic artificial intelligence to capture more intelligent information with less data, enabling faster, more accurate, and more reliable perception of the surroundings. Majority of the Company's revenue is generated from customers located in the United States followed by Europe, and Asia-Pacific.
About MYNZ Mainz Biomed N.V.
Mainz Biomed NV develops market-ready molecular genetic diagnostic solutions for life-threatening conditions. The company's flagship product is ColoAlert, is an accurate, non-invasive and easy-to-use, early-detection diagnostic test for colorectal cancer based on real-time Polymerase Chain Reaction-based (PCR) multiplex detection of molecular-genetic biomarkers in stool samples.